Pharmazz, Inc. is a clinical stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target critical care medicine. The company is developing several clinical-stage product candidates, PMZ-2010 (Centhaquine), PMZ-1620 (Sovateltide) and PMZ-2123 for which it holds global marketing rights.
Established in 2010, Pharmazz, Inc. is an emerging global pharmaceutical company. Focus of the company is to discover, acquire, develop and market novel pharmaceutical products for use in critical care and hospital settings.
Hypovolemic Shock (PMZ-2010 (Centhaquine))
Ischemic stroke (PMZ-1620 (Sovateltide))
Alzheimer's Disease (PMZ-1620 (Sovateltide))
Spinal Cord Injury (PMZ-1620 (Sovateltide))
Cardiac Arrest (PMZ-2010 (Centhaquine))
Opioid Tolerance (PMZ-2123)
Diabetic Ketoacidosis (PMZ-2123)
Post-Operative Pain (PMZ-2010 (Centhaquine))